Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Joseph Merola¹, Iain McInnes², Atul Deodhar³, Erhard Quebe-Fehling⁴, Maher Aassi⁴, Michael Peine⁴ and Nehal Mehta⁵, ¹Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
Abstract Number: 0057 • ACR Convergence 2021
Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab
Rita Torres¹, Daniel Sobral², Ana Fernandes³, Atlas Sardoo⁴, Miguel Bernardes⁵, Patrícia Pinto⁶, Helena Santos⁷, João Gomes⁸, Jose Tavares-Costa⁹, José Silva¹⁰, João Dias¹¹, Alexandra Bernardo⁵, Jean Gailard¹², Jean Armengaud¹³, Vladimir Benes¹⁴, Lúcia Domingues¹⁵, Sara Maia¹⁶, Jaime Branco¹⁷, Ana Varela¹⁸ and Fernando Santos¹⁹, ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Faculdade Ciências e Tecnologia, Lisboa, Lisboa, Portugal, ³Instituto de Tecnologia Química e Biológica, Lisboa, Portugal, ⁴CEDOC, NOVA Medical School, UNL, Lisboa, Lisboa, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁶Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ⁷Portuguese Institute of Rheumatology, Lisbon, Portugal, ⁸Hospital Egas Moniz, Lisboa, Lisboa, Portugal, ⁹Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, ¹⁰Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹¹Centro Hospitalar Médio Tejo, Abrantes, Portugal, ¹²Centre dénergie atomique; Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, ¹³Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, ¹⁴The European Molecular Biology Laboratory, Heidelberg, Germany, ¹⁵CEDOC - Chronic Diseases Research Center - Nova Medical School|Faculdade de Ciências Médicas, Lisboa, Lisboa, Portugal, ¹⁶NOVA Medical School, Nova University of Lisbon, Lisboa, Lisboa, Portugal, ¹⁷EpiDoC Unit, CEDOC, Nova Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, ¹⁸Instituto Tecnologia Química e Biológica; Universidade NOVA de Lisboa, Lisboa, Lisboa, Portugal, ¹⁹Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: The response to treatment in spondylarthropaties is heterogeneous, due to factors yet to be better described. For that reason, it is important to find…
Abstract Number: 0367 • ACR Convergence 2021
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Souzi Makri², Denis Poddubnyy³, Christine Bundy⁴, Laura Christen⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Victoria Navarro-Compán⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ³Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁴Cardiff University, Cardiff, Wales, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…
Abstract Number: 0575 • ACR Convergence 2021
World Mortality of Spondyloarthritis and Inflammatory Bowel Diseases in 2015 and Its Evolution Between 2001 and 2015
Olivier Fakih, Clement Prati, Daniel Wendling and Frank Verhoeven, Service de rhumatologie, CHU de Besançon, Besançon, France
Background/Purpose: There is little epidemiological data on mortality in spondyloarthritis (SpA). This study aimed to determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic…
Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Jean Liew¹, S. Reza Jafarzadeh², Maureen Dubreuil³, Susan Heckbert⁴, Stephen Mooney⁴, Matthew Brown⁵, Mariko Ishimori⁶, John Reveille⁷, Michael Ward⁸, Michael Weisman⁹ and Lianne Gensler¹⁰, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine/ VA Boston, Boston, MA, ⁴University of Washington, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁸Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…
Abstract Number: 1045 • ACR Convergence 2021
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Junming Chen, Xuechan Huang, Qidang Huang, Zhixiang Huang, Yukai Huang, Yuqi Liu, Lixin Huang, Shanmiao Sun, Zhuyi ji and Tianwang Li, Guangdong Second Provincial General Hospital, Guangzhou, China (People's Republic)
Background/Purpose: To investigate the composition of phospholipid fatty acids in erythrocyte membranes from patients with ankylosing spondylitis (AS), and determine the correlations between the percentage…
Abstract Number: 1919 • ACR Convergence 2021
Detection of Radiographic Sacroiliitis with an Artificial Neural Network in Patients with Suspicion of Axial Spondyloarthritis
Denis Poddubnyy¹, Fabian Proft², Kay-Geert Hermann², Laura Spiller², Stefan Niehues², Lisa Adams², Mikhail Protopopov², Valeria Rios Rodriguez², Burkhard Muche², Judith Rademacher², Murat Torgutalp², Keno Bressem² and Janis Vahldiek², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method for the diagnosis of axial spondyloarthritis (axial SpA). In many…
Abstract Number: 0063 • ACR Convergence 2021
Development of a Novel Cartilage Model Co-cultured with Conditioned Medium from Th17 Cells to Explore the Effect of IL-17A on Joint Tissue Remodeling
Solveig S. Groen¹, Christian S Thudium², Morten Karsdal³, Anne-Christine Bay-Jensen² and Signe Holm Nielsen⁴, ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, ⁴Nordic Bioscience and Technical University of Denmark, Biomedicine and Biotechnology, Kgs. Lyngby, Herlev, Denmark
Background/Purpose: In spondyloarthritis (SpA) Th17 cells play a critical role in activating the pathogenic chain leading to manifestations related to skin, joints and entheses. Elevated…
Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Miranda van Lunteren¹, Anne Boel¹, Clementina López Medina², Joachim Sieper³, Désirée van der Heijde⁴ and Floris van Gaalen¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
Abstract Number: 0748 • ACR Convergence 2021
Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia
Xenofon Baraliakos, Styliani Tsiami, Maria Claudia Gkelaki, Piet Dukatz, Uta Kiltz and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…
Abstract Number: 0911 • ACR Convergence 2021
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Thibaut Delépine¹, Peggy PHILIPPE², Emeline CAILLIAU³, Eric HOUVENAGEL⁴, Tristan Pascart⁵, Xavier DEPREZ⁶, Rene-Marc FLIPO⁷ and Jean-Guillaume LETAROUILLY², ¹Lille University Hospital, Lille, France, ²Rheumatology Department, University Hospital of Lille, Lille, France, ³Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, ⁴Rheumatology Department, Lille Catholic Hospitals, Lomme, France, ⁵Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁶Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…
Abstract Number: 1093 • ACR Convergence 2021
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Bindee Kuriya¹, Shadi Akhtari², Mohammad Movahedi³, Jacob Udell⁴, Patrick Lawler⁴, Paula Harvey⁵ and Lihi Eder⁴, ¹University of Toronto - Toronto, Toronto, ON, Canada, ²Women's College Hospital, University of Toronto, North York, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Inflammatory arthritis (IA) is associated with cardiovascular disease (CVD). Cardiac biomarkers may assist with CVD risk stratification. We aimed to estimate the prevalence, and…
Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Raj Sengupta¹, Shruti Narasimham², Borja Mato³, Matic Meglic³, Chiara Perella³, Paula Pamies⁴ and Paul Emery⁵, ¹The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…
Abstract Number: 0065 • ACR Convergence 2021
Altered Expression of Several miRNAs in Axial Spondyloarthritis Patients with High Disease Activity
Jiri Baloun¹, Kristyna Bubova¹, Aneta Pekacova¹, Monika Gregova², Sarka Forejtova¹, Jana Horinkova¹, Michal Tomcik³, Jindriska Gatterova¹, Jiri Vencovsky¹, Karel Pavelka³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Rheumatology Institute Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Recent studies have shown that microRNAs (miRNAs) play a role in various disorders, including immune mediated inflammatory diseases. Therefore, we studied relationship between miRNA…
Abstract Number: 0369 • ACR Convergence 2021
High Frequency of Complications in Axial Spondyloarthropathy Pregnancies: Emerging Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Phil Gallagher² and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²St Vincent's Hospital, Dublin, Ireland
Background/Purpose: National registries are excellent sources of data to allow analysis of inflammatory arthritis such as axial spondyloarthropathy (axSpA). Our understanding of axSpA has evolved…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].